The antibiotic streptothricin (ST) possesses an amino sugar bound to an L--lysine (-Lys) residue via a peptide bond. The peptide bond formation has been shown to be catalyzed by a nonribosomal peptide synthetase (NRPS) during ST biosynthesis. The focus of this study is the closely related ST analogue BD-12, which carries a glycine-derived side chain rather than a -Lys residue. Here, in Streptomyces luteocolor NBRC13826, we describe our biosynthetic studies of BD-12, which revealed that the peptide bond between the amino sugar and the glycine residue is catalyzed by a Fem-like enzyme (Orf11) in a tRNA-dependent manner rather than by an NRPS. Although there have been several reports of peptide bond-forming tRNA-dependent enzymes, to our knowledge, Orf11 is the first enzyme that can accept an amino sugar as a substrate. Our findings clearly demonstrate that the structural diversity of the side chains of ST-type compounds in nature is generated in an unusual manner via two distinct peptide bond-forming mechanisms. Moreover, the identification and functional analysis of Orf11 resulted in not only the production of new ST-related compounds, but also the provision of new insights into the structure-activity relationship of the ST-related antibiotics. (1), STs with an oligo(-Lys) consisting of two to seven residues have been identified (Fig. 1). ST-F inhibits protein biosynthesis in prokaryotic cells (2), and STs carrying the longer oligo(-Lys) side chains show higher levels of antibacterial activity. Moreover, STs strongly inhibit the growth of eukaryotes, such as yeasts (3-5), fungi (6), protozoa (7), insects (8), plants (9), and mammals (10-13). Although STs have been used effectively as selective agents for recombinant DNA work in some of these organisms, STs are not currently used therapeutically due to their inherent toxicity. In addition to the STs, it has been reported that Streptomyces strains produce ST analogues that possess a glycinederived side chain rather than the -Lys residue: 15), citromycin (16,17), glycinothricin (18), A-269A (19), and A-269A= (19) (Fig. 1). These analogues display potent antibacterial activities, although their molecular targets remain unclear. Also, like the STs, the ST analogues are not used clinically due to their toxicity.We previously identified the ST-biosynthetic gene cluster (accession no. AB684619) in Streptomyces rochei NBRC 12908 (Fig. 2) and elucidated the biosynthetic mechanisms of the oligo(-Lys) side chains (20). Nonribosomal peptide synthetases (NRPSs) are known to catalyze the assembly of a myriad of structurally complex peptide natural products (21). However, in the previous study, we identified three unique stand-alone NRPSs among the ST-biosynthetic enzymes and showed that they assembled the structurally simple peptide oligo(-Lys) (Fig. 3A). The biosynthesis is initiated by adenylation of -Lys in Orf5 (stand-alone adenylation [A] domain), and the resulting L--lysyl-O-AMP is loaded